Gilead Sciences, Inc. $GILD Stock: New England Research & Management Inc. Decreases Holdings

New England Research & Management Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.2% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 14,495 shares of the biopharmaceutical company’s stock after selling 6,575 shares during the period. New England Research & Management Inc.’s holdings in Gilead Sciences were worth $2,160,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Bank of Nova Scotia purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $100,056,000. Groupe la Francaise increased its holdings in shares of Gilead Sciences by 30.9% in the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after purchasing an additional 11,712 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $55,754,000. Baird Financial Group Inc. raised its stake in shares of Gilead Sciences by 3.6% during the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Gilead Sciences during the second quarter worth approximately $6,251,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GILD. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Thursday, October 8th. Truist Financial upped their price objective on shares of Gilead Sciences from $150.00 to $158.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Finally, HSBC raised their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $159.33.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. The trade was a 1.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the sale, the director owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock valued at $15,877,860 in the last three months. Insiders own 0.30% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Vir oncology collaboration expands Gilead’s pipeline. Gilead and Vir Biotechnology agreed to develop three novel cancer therapies, including next-generation T-cell engagers. The deal could provide Vir with up to approximately $1.74 billion in additional milestone payments, giving Gilead access to potential long-term oncology growth while diversifying its pipeline. Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
• Positive Sentiment: Investors are rotating toward defensive healthcare stocks. As investors reduce exposure to technology and chip stocks, major pharmaceutical companies—including Gilead—have traded near record highs. This rotation may be supporting demand for GILD because of the sector’s defensive characteristics and potential earnings support. Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
• Neutral Sentiment: Recent momentum has increased investor attention. GILD gained 2.57% in the prior session and closed at $157.48, while shares remain close to their 52-week high. Market commentary notes heightened investor interest, although analysts have expressed mixed views on the company’s prospects. Gilead Sciences rises higher than market: Key facts
• Negative Sentiment: Two senior executives reported planned stock sales. CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares at an average price of $156.22. Both transactions were executed under pre-arranged Rule 10b5-1 plans, limiting their significance as a bearish signal; each executive continues to hold a substantial position. Gilead CFO Form 4 filing

Gilead Sciences Stock Performance

NASDAQ GILD traded down $1.18 on Friday, hitting $156.19. 7,770,853 shares of the company’s stock were exchanged, compared to its average volume of 5,976,056. The firm has a market cap of $193.67 billion, a price-to-earnings ratio of -58.50 and a beta of 0.31. The firm’s 50-day moving average price is $147.19 and its two-hundred day moving average price is $137.29. Gilead Sciences, Inc. has a fifty-two week low of $114.02 and a fifty-two week high of $160.51. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the firm earned $2.01 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were given a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.